Australia's most trusted
source of pharma news
Saturday, 15 March 2025
Posted 11 March 2025 PM
Australian HCPs are flocking to a new service sponsored by AstraZeneca and Roche to access the personalised medicine revolution.
The Weekly Virtual Molecular Tumour Boards are provided by a collaboration between advanced genomic profiling company LifeStrands and the Private Cancer Physicians of Australia (PCPA). It's funded by early sponsors AstraZeneca and Roche.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.